Literature DB >> 35925271

[Targeted treatment of non-small cell lung cancer].

Matthias Scheffler1, Sebastian Michels2, Lucia Nogova2.   

Abstract

Non-small cell lung cancer (NSCLC) has made a remarkable development in recent decades with respect to its perception. In the late 1990s it was the "problem child" as the main cause of cancer with increasing tendencies, especially in women and with a pronounced stigmatization. It is now the role model as a biologically rational targeted treatment based on molecular dependencies of the tumor with a vast improvement of the traditionally poor survival times. Molecular tumor boards have long followed the NSCLC example in the assessment of targeted treatment approaches for other tumor entities. This review article gives an overview of the current possibilities for targeted treatment of NSCLC, which nowadays are applicable for nearly one third of all patients with NSCLC.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Drug resistance, neoplasm; Molecular genetic analysis; Mutation/BRAF; Mutation/EGFR; Mutation/KRAS

Mesh:

Year:  2022        PMID: 35925271     DOI: 10.1007/s00108-022-01372-2

Source DB:  PubMed          Journal:  Inn Med (Heidelb)        ISSN: 2731-7080


  56 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

3.  Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.

Authors:  Katharina König; Martin Peifer; Jana Fassunke; Michaela A Ihle; Helen Künstlinger; Carina Heydt; Katrin Stamm; Frank Ueckeroth; Claudia Vollbrecht; Marc Bos; Masyar Gardizi; Matthias Scheffler; Lucia Nogova; Frauke Leenders; Kerstin Albus; Lydia Meder; Kerstin Becker; Alexandra Florin; Ursula Rommerscheidt-Fuss; Janine Altmüller; Michael Kloth; Peter Nürnberg; Thomas Henkel; Sven-Ernö Bikár; Martin L Sos; William J Geese; Lewis Strauss; Yon-Dschun Ko; Ulrich Gerigk; Margarete Odenthal; Thomas Zander; Jürgen Wolf; Sabine Merkelbach-Bruse; Reinhard Buettner; Lukas C Heukamp
Journal:  J Thorac Oncol       Date:  2015-07       Impact factor: 15.609

4.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

5.  Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.

Authors:  D Ross Camidge; Rafal Dziadziuszko; Solange Peters; Tony Mok; Johannes Noe; Malgorzata Nowicka; Shirish M Gadgeel; Parneet Cheema; Nick Pavlakis; Filippo de Marinis; Byoung Chul Cho; Li Zhang; Denis Moro-Sibilot; Ting Liu; Walter Bordogna; Bogdana Balas; Barbara Müller; Alice T Shaw
Journal:  J Thorac Oncol       Date:  2019-03-20       Impact factor: 15.609

6.  First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

Authors:  Luis Paz-Ares; Tudor-Eliade Ciuleanu; Manuel Cobo; Michael Schenker; Bogdan Zurawski; Juliana Menezes; Eduardo Richardet; Jaafar Bennouna; Enriqueta Felip; Oscar Juan-Vidal; Aurelia Alexandru; Hiroshi Sakai; Alejo Lingua; Pamela Salman; Pierre-Jean Souquet; Pedro De Marchi; Claudio Martin; Maurice Pérol; Arnaud Scherpereel; Shun Lu; Thomas John; David P Carbone; Stephanie Meadows-Shropshire; Shruti Agrawal; Abderrahim Oukessou; Jinchun Yan; Martin Reck
Journal:  Lancet Oncol       Date:  2021-01-18       Impact factor: 41.316

7.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

8.  First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.

Authors:  Alice T Shaw; Todd M Bauer; Filippo de Marinis; Enriqueta Felip; Yasushi Goto; Geoffrey Liu; Julien Mazieres; Dong-Wan Kim; Tony Mok; Anna Polli; Holger Thurm; Anna M Calella; Gerson Peltz; Benjamin J Solomon
Journal:  N Engl J Med       Date:  2020-11-19       Impact factor: 91.245

9.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

10.  Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.

Authors:  A T Shaw; G J Riely; Y-J Bang; D-W Kim; D R Camidge; B J Solomon; M Varella-Garcia; A J Iafrate; G I Shapiro; T Usari; S C Wang; K D Wilner; J W Clark; S-H I Ou
Journal:  Ann Oncol       Date:  2019-07-01       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.